Your browser doesn't support javascript.
loading
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.
Adams, S; Schmid, P; Rugo, H S; Winer, E P; Loirat, D; Awada, A; Cescon, D W; Iwata, H; Campone, M; Nanda, R; Hui, R; Curigliano, G; Toppmeyer, D; O'Shaughnessy, J; Loi, S; Paluch-Shimon, S; Tan, A R; Card, D; Zhao, J; Karantza, V; Cortés, J.
Afiliación
  • Adams S; Department of Medicine, Perlmutter Cancer Center, New York University School of Medicine, New York, USA. Electronic address: Sylvia.Adams@nyumc.org.
  • Schmid P; Centre for Experimental Cancer Medicin, Barts Cancer Institute, Queen Mary University London, London, UK.
  • Rugo HS; Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco.
  • Winer EP; Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.
  • Loirat D; Institut Curie, Paris, France.
  • Awada A; Oncology Medicine Departmen, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium.
  • Cescon DW; Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
  • Iwata H; Aichi Cancer Center Hospital, Nagoya, Japan.
  • Campone M; Institut de Cancerologie de l'Ouest, Nantes, France.
  • Nanda R; Department of Medicin, Section of Hematology/Oncology, The University of Chicago, Chicago, USA.
  • Hui R; Westmead Hospital and the University of Sydney, Sydney, Australia.
  • Curigliano G; Department of Oncology and Hematology, University of Milano, Milan; IEO, European Institute of Oncology IRCCS, Milano, Milan, Italy.
  • Toppmeyer D; Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, USA.
  • O'Shaughnessy J; Baylor University Medical Center, Dallas; Texas Oncology, Dallas; US Oncology, Dallas, USA.
  • Loi S; Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Paluch-Shimon S; Breast Cancer Service for Young Women, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
  • Tan AR; Levine Cancer Institute, Atrium Health, Charlotte.
  • Card D; Merck & Co., Inc., Kenilworth, USA.
  • Zhao J; Merck & Co., Inc., Kenilworth, USA.
  • Karantza V; Merck & Co., Inc., Kenilworth, USA.
  • Cortés J; Breast Cancer Program, Vall d'Hebron Institute of Oncology, Barcelona; Ramon y Cajal University Hospital, Madrid; IOB Institute of Oncology, Quiron Group, Barcelona, Spain.
Ann Oncol ; 30(3): 397-404, 2019 03 01.
Article en En | MEDLINE | ID: mdl-30475950
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales Humanizados / Antígeno B7-H1 / Neoplasias de la Mama Triple Negativas Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales Humanizados / Antígeno B7-H1 / Neoplasias de la Mama Triple Negativas Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article